ArticlePloS one2023
Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review.
Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Inpatient treatments for adults with anorexia nervosa: a systematic review of literature.Eating and weight disorders : EWD · 2024Pooled it
- Anorexia Nervosa and Emotional Dysregulation: A Longitudinal Study on the Characteristics and Clinical Implications in a Group of Female Adolescents.Children (Basel, Switzerland) · 2026Article
- Could refeeding-associated gynaecomastia occur during recovery from anorexia nervosa? A hypothesis-generating review.Frontiers in endocrinology · 2026Review
- Food for thought: re-emergence of tardive dyskinesia amid nutritional rehabilitation of atypical anorexia nervosa; a case report.Journal of eating disorders · 2025Article
- Decoding the Spectrum of Anorexia Nervosa: Clinical Impact, Molecular Insights, and Therapeutic Perspectives.Biomolecules · 2025Review
- What does taking olanzapine mean to young people with anorexia nervosa and their families? Findings from the OPEN feasibility trial.Journal of eating disorders · 2025Article
- Long-acting injectable paliperidone palmitate for severe anorexia nervosa and comorbid autism spectrum disorder: A case report.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Lived experiences of adolescents with anorexia nervosa and their parents during olanzapine treatment: a qualitative study.Journal of eating disorders · 2025Article
- Use of atypical antipsychotics in individuals with anorexia nervosa.The mental health clinician · 2025Article
- Understanding Bone Density Loss in Eating Disorders: Contributions of Weight Suppression and Speed of Weight Loss.Journal of clinical medicine · 2024Article
- Antipsychotic drugs for anorexia nervosa.The Cochrane database of systematic reviews · 2024Article
- Olanzapine use for the treatment of adolescents with anorexia nervosa - reflecting on research and clinical practice.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2024Article
- A feasibility trial of olanzapine for young people with Anorexia Nervosa (OPEN): clinicians' perspectives.Journal of eating disorders · 2024Article
- Autistic traits and perspective taking in youths with anorexia nervosa: an exploratory clinical and eye tracking study.Journal of eating disorders · 2024Article
- Psychopharmacology Review for Eating Disorders Among Children, Adolescents, and Adults.Focus (American Psychiatric Publishing) · 2024Review
- Innovative and Emerging Treatments for Anorexia Nervosa.Focus (American Psychiatric Publishing) · 2024Article
- Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part II.Journal of psychopharmacology (Oxford, England) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSecond-generation antipsychotics (SGAs) are frequently prescribed for the treatment of resistant anorexia nervosa. However, few clinical trials have been conducted so far and no pharmacological treatment has yet been approved by the Food and Drug Administration. The aim of this paper is to conduct a systematic scoping review exploring the effectiveness and safety of atypical antipsychotics in anorexia nervosa (AN).
methodWe conducted a systematic scoping review of the effectiveness and tolerability of SGAs in the management of AN. We included articles published from January 1, 2000, through September 12, 2022 from the PubMed and PsycInfo databases and a complementary manual search. We selected articles about adolescents and adults treated for AN by four SGAs (risperidone, quetiapine, aripiprazole or olanzapine). This work complies with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for scoping reviews (PRIMA-ScR) and was registered in the Open Science Framework (OSF) repository.
resultsThis review included 55 articles: 48 assessing the effectiveness of SGAs in AN and 7 focusing only on their tolerability and safety. Olanzapine is the treatment most frequently prescribed and studied with 7 randomized double-blind controlled trials. Other atypical antipsychotics have been evaluated much less often, such as aripiprazole (no randomized trials), quetiapine (two randomized controlled trials), and risperidone (one randomized controlled trial). These treatments are well tolerated with mild and transient adverse effects in this population at particular somatic risk. DISCUSSION: Limitations prevent the studies both from reaching conclusive, reliable, robust, and reproducible results and from concluding whether or not SGAs are effective in anorexia nervosa. Nonetheless, they continue to be regularly prescribed in clinical practice. International guidelines suggest that olanzapine and aripiprazole can be interesting in severe or first-line resistant clinical situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.